Туберкулез и болезни лёгких (Aug 2018)

TREATMENT OF TUBERCULOSIS PATIENTS WITH EXTENSIVE DRUG RESISTANCE USING NEW ANTI-TUBERCULOSIS DRUGS IN THE CIVILIAN COMMUNITY OF ARKHANGELSK REGION

  • Anastasiya I. Gayda,
  • Oksana M. Sveshnikova,
  • Viktoriya N. Verkhovaya,
  • Svetlana V. Makhmaeva,
  • Elena I. Nikishova,
  • Andrey O. Maryandyshev

DOI
https://doi.org/10.21292/2075-1230-2018-96-7-5-10
Journal volume & issue
Vol. 96, no. 7
pp. 5 – 10

Abstract

Read online

The objective: to assess treatment outcomes in tuberculosis patients with extensive drug resistance (XDR TB) treated by new anti-tuberculosis drugs in the civilian community of Arkhangelsk Region.The analysis included all cases of XDR TB registered in the civilian community of Arkhangelsk Region from November 2006 to December 2013; treatment outcomes were assessed in 21 patients who were treated by regimens containing new anti-tuberculosis drugs (bedaquiline, delamanid, linezolid, clofazimine, imipenem with amoxiclav). 16 patients were treated by regimens containing 4 new anti-tuberculosis drugs. 2 patients were treated by regimen IV containing two drugs – bedaquiline, linezolid and bedaquiline, clofazimine; and 3 patients with regimens containing bedaquiline only.From November 2006 to December 2017, 175 XDR TB patients were registered in Arkhangelsk Region. The effective chemotherapy using new drugs made 57%, and mortality made 4.7%. In-take of new anti-tuberculosis drugs was accompanied side effects of minor and moderate degree.New anti-tuberculosis drugs are to be studied further in order to work out the most effective regimens for treatment of XDR TB patients.

Keywords